
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:1975</ns1:identifier>
    <ns1:title language="en">Protein Expression of Folate Receptor Alpha in Adenoid Cystic Carcinoma of the Head and Neck</ns1:title>
    <ns1:language>en</ns1:language>
    <ns1:description language="en">Abstract: Folate receptor alpha (FRÎ±) is overexpressed in various cancer entities while expression in normal tissue is limited. Thus, FRÎ± is an attractive target in cancer therapy. Currently, various therapeutic and diagnostic approaches are under investigation in clinical trials. The aim of this study was to assess the expression and clinical relevance of FRÎ± in adenoid cystic carcinoma of the head and neck.In this retrospective cohort study, 43 patients with adenoid cystic carcinoma (ACC) of the head and neck were included. FRÎ± expression was analyzed in tumor tissue and tumor-free margin in a tissue microarray using immunohistochemical staining. Protein levels were correlated with clinical parameters.FRÎ± staining was positive in 47% of ACC patients. The tumor-free margin was positive in 22%. Patients with positive tumor tissue showed positive margin staining in 55%. FRÎ± expression was not associated with the clinical parameters (sex, age, staging, grading, perineural invasion, lymphovascular invasion).FRÎ± expression is common in ACC of the head and neck. Therefore, FRÎ± should be further evaluated as a therapeutic target in ACC.</ns1:description>
    <ns1:keyword language="de">Antibody-Drug Conjugate; Mirvetuximab Soravtansine; Ovarian-Carcinoma; Phase-Iii; Chemotherapy; Combination; Trial</ns1:keyword>
    <ns2:identifiers>
      <ns2:resource>1552099</ns2:resource>
      <ns2:identifier>10.2147/OTT.S351500</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2023-08-11T08:01:37.968Z</ns1:upload_date>
    <ns1:status>44</ns1:status>
    <ns2:peer_reviewed>yes</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Julia</ns3:firstname>
        <ns3:lastname>Schnoell</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:orcid>0000-0001-9772-4395</ns3:orcid>
      </ns1:entity>
      <ns1:entity seq="7">
        <ns3:firstname>Bernhard J.</ns3:firstname>
        <ns3:lastname>Jank</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="6">
        <ns3:firstname>Lorenz</ns3:firstname>
        <ns3:lastname>Kadletz-Wanke</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="5">
        <ns3:firstname>Stefan</ns3:firstname>
        <ns3:lastname>Stoiber</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="4">
        <ns3:firstname>Elisabeth</ns3:firstname>
        <ns3:lastname>Gurnhofer</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="3">
        <ns3:firstname>Michaela</ns3:firstname>
        <ns3:lastname>Schlederer</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="2">
        <ns3:firstname>Gregor</ns3:firstname>
        <ns3:lastname>Heiduschka</ns3:lastname>
        <ns3:institution>Medical University of Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="1">
        <ns3:firstname>Lukas</ns3:firstname>
        <ns3:lastname>Kenner</ns3:lastname>
        <ns3:institution>University of Veterinary Medicine Vienna / Medical University of Vienna / CBmed GmbH - Center for Biomarker Research in Medicine</ns3:institution>
        <ns3:type>person</ns3:type>
        <ns3:orcid>0000-0003-2184-1338</ns3:orcid>
      </ns1:entity>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>application/pdf</ns1:format>
    <ns1:size>2602736</ns1:size>
    <ns1:location>https://phaidra.vetmeduni.ac.at/o:1975</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>17</ns1:license>
  </ns1:rights>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1552253</ns8:hoschtyp>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:name_magazine language="de">Oncotargets and Therapy</ns12:name_magazine>
    <ns12:pagination>8</ns12:pagination>
    <ns12:volume>15</ns12:volume>
    <ns12:from_page>531</ns12:from_page>
    <ns12:to_page>538</ns12:to_page>
    <ns12:publisher>Dove Medical Press LTD</ns12:publisher>
    <ns12:releaseyear>2022</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>